Inclusion Criteria:

- History of histologically confirmed colorectal adenocarcinoma metastatic to the liver
with no clinical or radiographic evidence of extrahepatic disease. Confirmation of
diagnosis must be performed at MSKCC.

- Completely resected hepatic metastases without current evidence of other metastatic
disease.

- Lab values within 14 days prior to registration:

- WBC > or = to 3.0 K/uL

- ANC > 1.5 K/uL

- Platelets > or = to 100,000/uL

- Creatinine <1.5 mg/dL

- HGB > or = to 9 gm/dL Renal function (≤ 10 days prior to enrollment/randomization).

- Creatinine ≤1.5 mg/dL or creatinine clearance ≥ 50 mL/min calculated by the

Cockcroft-Gault method as follows:

- Male creatinine clearance = (140 -age in years) x (weight in Kg) / (serum Cr in mg/dl
x 72)

- Female creatinine clearance = (140 - age in years) x (weight in Kg) x 0.85 / (serum
Cr in mg/dl x 72) (use of creatinine clearance per protocol based on chemotherapy
regimen) Hepatic function, as follows: (≤ 10 days prior to enrollment/randomization)

- Aspartate aminotransferase (AST) (≤ 5 x ULN)

- Alanine aminotransferase (ALT) (≤ 5 x ULN)

- Total Bilirubin ≤ 1.5 mg/dl

- Magnesium ≥ lower limit of normal (≤ 48 hours prior to enrollment/ randomization.)

- Calcium ≥ lower limit of normal (≤ 48 hours prior to enrollment/ randomization.)

- Prior chemotherapy is acceptable if last dose given ≥ 3 weeks prior to registration
to this study. [Note: no chemotherapy to be given after resection of liver lesions
prior to treatment on this study.]

- Any investigational agent is acceptable if administered ≤ 30 days before
enrollment/randomization

- KPS ≥ 60% (ECOG (or Karnofsky) performance status (preferably 0 or 1/≥ 60% for
Karnofsky)

- Histologically confirmed KRAS wild type(G12 mutations are not eligible. All other
mutations are eligible).

- Paraffin-embedded tumor tissue obtained from the primary tumor or metastasis

Exclusion Criteria:

- Patients < 18 years of age.

- Prior radiation to the liver (Prior radiation therapy to the pelvis is acceptable if
completed at least 4 weeks prior to registration.)

- Active infection, ascites, hepatic encephalopathy.

- Prior treatment with HAI FUDR.

- Patients who have had prior anti-EGFr antibody therapy inhibitors and who have not
responded to this treatment will be excluded. However, patients who have responded to
prior anti-EGFR therapy are eligible.)

- Female patients who are pregnant or lactating - or planning to become pregnant within
6 months after the end of the treatment (female patients of child-bearing potential
must have negative pregnancy test ≤ 72 hours before enrollment).

- If a patient has any serious medical problems which may preclude receiving this type
of treatment.

- Patients with current evidence of hepatitis A, B, C (ie, active hepatitis)

- Patients with history or known presence of primary CNS tumors, seizures not well
controlled with standard medical therapy, or history of stroke will also be excluded.

- History of allergic reactions attributed to compounds of similar chemical or biologic
composition to Panitumumab.

- Serious or non-healing active wound, ulcer, or bone fracture.

- History of interstitial lung disease e.g. pneumonitis or pulmonary fibrosis or
evidence of interstitial lung disease on baseline chest CT scan.

- Patients who have a diagnosis of Gilbert's disease.

- History of other malignancy, except:

- Malignancy treated with curative intent and with no known active disease present for
≥ 3 years prior to randomization and felt to be at low risk for recurrence by the
treating physician

- Adequately treated non-melanomatous skin cancer or lentigo maligna without evidence
of disease

- Adequately treated cervical carcinoma in situ without evidence of disease